Cost-effectiveness evaluation of the use of PCSK9 inhibitors Fernando Civeira; Juan Pedro-Botet;

Impact of the presence and type of cardiovascular disease on the risk of mortality in type 2 diabetic patients: The DIABET-IC trial José Antonio Gimeno Orna; Ana Belén Mañas Martínez; Luis Rodríguez Padial; Manuel Anguita Sánchez; Vivencio Barrios; Javier Muñiz García; Antonio Pérez Pérez;

Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes Ana Romero; Gemma Llauradó; José-Miguel González-Clemente;